Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Circulating Tumor Cells Market, By Technology
7.1. Circulating Tumor Cells Market, by Technology, 2020-2030
7.1.1. CTC Detection & Enrichment Methods
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. CTC Direct Detection Methods
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. CTC Analysis
7.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Circulating Tumor Cells Market, By Application
8.1. Circulating Tumor Cells Market, by Application, 2020-2030
8.1.1. Clinical/ Liquid Biopsy
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Research
8.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Circulating Tumor Cells Market, By Product
9.1. Circulating Tumor Cells Market, by Product, 2020-2030
9.1.1. Kits & Reagents
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. Blood Collection Tubes
9.1.2.1. Market Revenue and Forecast (2016-2030)
9.1.3. Devices or Systems
9.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 10. Global Circulating Tumor Cells Market, By Specimen
10.1. Circulating Tumor Cells Market, by Specimen, 2020-2030
10.1.1. Blood
10.1.1.1. Market Revenue and Forecast (2016-2030)
10.1.2. Bone Marrow
10.1.2.1. Market Revenue and Forecast (2016-2030)
10.1.3. Other Body Fluids
10.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 11. Global Circulating Tumor Cells Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Technology (2016-2030)
11.1.2. Market Revenue and Forecast, by Application (2016-2030)
11.1.3. Market Revenue and Forecast, by Product (2016-2030)
11.1.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.1.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.1.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Technology (2016-2030)
11.1.6.2. Market Revenue and Forecast, by Application (2016-2030)
11.1.6.3. Market Revenue and Forecast, by Product (2016-2030)
11.1.6.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Technology (2016-2030)
11.2.2. Market Revenue and Forecast, by Application (2016-2030)
11.2.3. Market Revenue and Forecast, by Product (2016-2030)
11.2.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.2.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.2.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Technology (2016-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2016-2030)
11.2.6.3. Market Revenue and Forecast, by Product (2016-2030)
11.2.6.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Technology (2016-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2016-2030)
11.2.7.3. Market Revenue and Forecast, by Product (2016-2030)
11.2.7.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Technology (2016-2030)
11.2.8.2. Market Revenue and Forecast, by Application (2016-2030)
11.2.8.3. Market Revenue and Forecast, by Product (2016-2030)
11.2.8.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Technology (2016-2030)
11.3.2. Market Revenue and Forecast, by Application (2016-2030)
11.3.3. Market Revenue and Forecast, by Product (2016-2030)
11.3.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.3.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.3.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Technology (2016-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2016-2030)
11.3.6.3. Market Revenue and Forecast, by Product (2016-2030)
11.3.6.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Technology (2016-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2016-2030)
11.3.7.3. Market Revenue and Forecast, by Product (2016-2030)
11.3.7.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Technology (2016-2030)
11.3.8.2. Market Revenue and Forecast, by Application (2016-2030)
11.3.8.3. Market Revenue and Forecast, by Product (2016-2030)
11.3.8.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Technology (2016-2030)
11.4.2. Market Revenue and Forecast, by Application (2016-2030)
11.4.3. Market Revenue and Forecast, by Product (2016-2030)
11.4.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.4.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.4.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Technology (2016-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2016-2030)
11.4.6.3. Market Revenue and Forecast, by Product (2016-2030)
11.4.6.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Technology (2016-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2016-2030)
11.4.7.3. Market Revenue and Forecast, by Product (2016-2030)
11.4.7.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Technology (2016-2030)
11.4.8.2. Market Revenue and Forecast, by Application (2016-2030)
11.4.8.3. Market Revenue and Forecast, by Product (2016-2030)
11.4.8.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.5.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.5.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Technology (2016-2030)
11.5.6.2. Market Revenue and Forecast, by Application (2016-2030)
11.5.6.3. Market Revenue and Forecast, by Product (2016-2030)
11.5.6.4. Market Revenue and Forecast, by Specimen (2016-2030)
Chapter 12. Company Profiles
12.1. QIAGEN
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bio-Techne Corporation
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Precision for Medicine
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. AVIVA Biosciences
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. BIOCEPT, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. BioCEP Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Fluxion Biosciences, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Greiner Bio One International GmbH
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Ikonisys Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Miltenyi Biotec
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
12.11. IVDiagnostics
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance
12.11.4. Recent Initiatives
12.12. BioFluidica
12.12.1. Company Overview
12.12.2. Product Offerings
12.12.3. Financial Performance
12.12.4. Recent Initiatives
12.13. Canopus Bioscience Ltd.
12.13.1. Company Overview
12.13.2. Product Offerings
12.13.3. Financial Performance
12.13.4. Recent Initiatives
12.14. Biolidics Limited
12.14.1. Company Overview
12.14.2. Product Offerings
12.14.3. Financial Performance
12.14.4. Recent Initiatives
12.15. Creativ MicroTech, Inc.
12.15.1. Company Overview
12.15.2. Product Offerings
12.15.3. Financial Performance
12.15.4. Recent Initiatives
12.16. LungLife AI, Inc.
12.16.1. Company Overview
12.16.2. Product Offerings
12.16.3. Financial Performance
12.16.4. Recent Initiatives
12.17. Epic Sciences
12.17.1. Company Overview
12.17.2. Product Offerings
12.17.3. Financial Performance
12.17.4. Recent Initiatives
12.18. Rarecells Diagnostics
12.18.1. Company Overview
12.18.2. Product Offerings
12.18.3. Financial Performance
12.18.4. Recent Initiatives
12.19. ScreenCell
12.19.1. Company Overview
12.19.2. Product Offerings
12.19.3. Financial Performance
12.19.4. Recent Initiatives
12.20. Menarini Silicon Biosystems
12.20.1. Company Overview
12.20.2. Product Offerings
12.20.3. Financial Performance
12.20.4. Recent Initiatives
12.21. LineaRx, Inc. (Vitatex, Inc.)
12.21.1. Company Overview
12.21.2. Product Offerings
12.21.3. Financial Performance
12.21.4. Recent Initiatives
12.22. Sysmex Corporation
12.22.1. Company Overview
12.22.2. Product Offerings
12.22.3. Financial Performance
12.22.4. Recent Initiatives
12.23. STEMCELL Technologies, Inc.
12.23.1. Company Overview
12.23.2. Product Offerings
12.23.3. Financial Performance
12.23.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
Glossary of Terms